uniQure (NASDAQ:QURE) CFO Christian Klemt Sells 12,000 Shares

uniQure N.V. (NASDAQ:QURE) CFO Christian Klemt sold 12,000 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $108,720.00. Following the completion of the transaction, the chief financial officer directly owned 226,581 shares of the company’s stock, valued at approximately $2,052,823.86. The trade was a 5.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Christian Klemt also recently made the following trade(s):

• On Wednesday, February 25th, Christian Klemt sold 6,217 shares of uniQure stock. The stock was sold at an average price of $23.86, for a total value of $148,337.62.

uniQure Stock Up 34.0%

Shares of NASDAQ:QURE traded up $3.62 during mid-day trading on Friday, reaching $14.27. 16,602,429 shares of the stock were exchanged, compared to its average volume of 3,442,688. The stock’s 50 day simple moving average is $22.25 and its 200-day simple moving average is $29.44. uniQure N.V. has a one year low of $7.76 and a one year high of $71.50. The company has a market cap of $892.30 million, a P/E ratio of -4.14 and a beta of 0.73. The company has a quick ratio of 7.12, a current ratio of 10.43 and a debt-to-equity ratio of 0.25.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.93) by $0.37. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. The company had revenue of $5.57 million during the quarter, compared to analysts’ expectations of $4.84 million. As a group, equities research analysts predict that uniQure N.V. will post -3.75 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Barclays started coverage on shares of uniQure in a research note on Tuesday, January 27th. They set an “equal weight” rating and a $31.00 price objective for the company. Wall Street Zen cut uniQure from a “hold” rating to a “sell” rating in a research report on Sunday, January 11th. William Blair reaffirmed a “market perform” rating on shares of uniQure in a research report on Tuesday, November 11th. Wells Fargo & Company reissued an “equal weight” rating and issued a $15.00 price objective (down from $60.00) on shares of uniQure in a report on Tuesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of uniQure in a report on Wednesday, January 21st. Seven analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $34.33.

Key Stories Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Neutral Sentiment: Mizuho issued a neutral rating on QURE, keeping some analyst coverage tepid rather than bullish. Read More.
• Negative Sentiment: A senior FDA official publicly called uniQure’s Huntington’s disease therapy unsuccessful and defended the agency’s call for a new randomized, placebo‑controlled study — a move that raises the likelihood of delays and additional trials before any BLA. Read More.
• Negative Sentiment: Broad media coverage amplifies regulatory risk: multiple outlets (WSJ, CNBC, FierceBiotech, BioSpace) report public rebukes from FDA/HHS and intensifying back‑and‑forth with uniQure — increasing reputational and approval uncertainty. Read More.
• Negative Sentiment: Numerous class‑action and shareholder‑lawsuit notices filed and circulated by law firms (lead‑plaintiff deadline April 13, 2026) — these raise potential legal liability, management distraction, and ongoing downward pressure on the share price. Read More.
• Negative Sentiment: Analyst actions have turned negative: Chardan cut its price target and other outlets report pessimistic forecasts (Goldman Sachs coverage noted), contributing to recent downgrades and reduced sell‑side enthusiasm. Read More.
• Negative Sentiment: Multiple insiders (including the CEO and CFO) sold shares on March 4 at ~$9.06 — the CEO, CFO and other insiders reduced holdings by low single‑digit to ~5% amounts. Insider selling can be perceived negatively by the market even though insiders still hold large positions. Read More.
• Negative Sentiment: Short‑term price shock: Zacks and other outlets report the stock plunged ~32% in a week after the FDA said AMT‑130 Phase I/II data are insufficient as primary evidence for a marketing application — underscores how quickly regulatory comments can swing valuation. Read More.

Institutional Investors Weigh In On uniQure

Several hedge funds have recently added to or reduced their stakes in the business. Woodline Partners LP boosted its position in uniQure by 25.0% during the first quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after purchasing an additional 35,175 shares during the period. Teacher Retirement System of Texas bought a new stake in shares of uniQure during the second quarter worth approximately $151,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of uniQure during the second quarter worth approximately $215,000. SG Americas Securities LLC acquired a new position in shares of uniQure in the second quarter valued at approximately $1,321,000. Finally, Main Management ETF Advisors LLC increased its stake in shares of uniQure by 1.6% during the second quarter. Main Management ETF Advisors LLC now owns 56,420 shares of the biotechnology company’s stock worth $786,000 after purchasing an additional 912 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.